CareDx, Inc (NASDAQ:CDNA) Shares Purchased by nVerses Capital LLC

nVerses Capital LLC increased its holdings in shares of CareDx, Inc (NASDAQ:CDNA) by 175.0% during the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 3,300 shares of the company’s stock after acquiring an additional 2,100 shares during the quarter. nVerses Capital LLC’s holdings in CareDx were worth $103,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. GAMMA Investing LLC raised its stake in CareDx by 1,021.8% during the second quarter. GAMMA Investing LLC now owns 2,210 shares of the company’s stock worth $34,000 after acquiring an additional 2,013 shares during the period. Plato Investment Management Ltd acquired a new stake in CareDx during the second quarter worth about $62,000. Creative Planning acquired a new stake in CareDx during the third quarter worth about $204,000. IQ EQ FUND MANAGEMENT IRELAND Ltd acquired a new stake in CareDx during the third quarter worth about $206,000. Finally, CWM LLC raised its stake in CareDx by 560.1% during the third quarter. CWM LLC now owns 7,604 shares of the company’s stock worth $237,000 after acquiring an additional 6,452 shares during the period.

CareDx Price Performance

CareDx stock opened at $23.98 on Monday. The firm has a 50 day simple moving average of $29.62 and a 200-day simple moving average of $19.78. The stock has a market capitalization of $1.25 billion, a PE ratio of -7.01 and a beta of 1.77. CareDx, Inc has a 12-month low of $4.80 and a 12-month high of $34.84.

CareDx (NASDAQ:CDNA) last posted its quarterly earnings data on Wednesday, July 31st. The company reported ($0.03) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.40) by $0.37. The business had revenue of $92.27 million during the quarter, compared to analysts’ expectations of $67.20 million. CareDx had a negative net margin of 53.73% and a negative return on equity of 53.65%. On average, analysts forecast that CareDx, Inc will post -0.84 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other CareDx news, insider Alexander L. Johnson sold 21,557 shares of CareDx stock in a transaction that occurred on Wednesday, August 21st. The shares were sold at an average price of $32.58, for a total transaction of $702,327.06. Following the transaction, the insider now directly owns 284,983 shares in the company, valued at approximately $9,284,746.14. The trade was a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. In other CareDx news, insider Alexander L. Johnson sold 21,557 shares of CareDx stock in a transaction on Wednesday, August 21st. The shares were sold at an average price of $32.58, for a total transaction of $702,327.06. Following the completion of the sale, the insider now owns 284,983 shares of the company’s stock, valued at $9,284,746.14. This trade represents a 0.00 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available at this hyperlink. Also, insider Alexander L. Johnson sold 34,231 shares of CareDx stock in a transaction on Monday, August 19th. The shares were sold at an average price of $33.55, for a total transaction of $1,148,450.05. Following the sale, the insider now directly owns 284,983 shares of the company’s stock, valued at $9,561,179.65. This trade represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 91,340 shares of company stock worth $3,025,415. 4.20% of the stock is owned by insiders.

Wall Street Analysts Forecast Growth

Several research analysts have commented on the stock. StockNews.com upgraded shares of CareDx from a “hold” rating to a “buy” rating in a research report on Thursday. BTIG Research upgraded shares of CareDx from a “neutral” rating to a “buy” rating and set a $40.00 target price for the company in a research report on Monday, August 19th. HC Wainwright restated a “neutral” rating on shares of CareDx in a research report on Thursday, August 1st. Wells Fargo & Company assumed coverage on shares of CareDx in a research report on Tuesday, August 27th. They issued an “underweight” rating and a $28.00 target price for the company. Finally, The Goldman Sachs Group upped their target price on shares of CareDx from $26.00 to $35.00 and gave the stock a “buy” rating in a research report on Wednesday, October 16th. One equities research analyst has rated the stock with a sell rating, two have assigned a hold rating and five have given a buy rating to the company. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus price target of $30.60.

CareDx Company Profile

CareDx, Inc engages in the discovery, development, and commercialization of diagnostic solutions for transplant patients and caregivers in the United States and internationally. It also provides AlloSure Kidney, a donor-derived cell-free DNA (dd-cfDNA) solution for kidney transplant patients; AlloMap Heart, a gene expression solution for heart transplant patients; AlloSure Heart, a dd-cfDNA solution for heart transplant patients; and AlloSure Lung, a dd-cfDNA solution for lung transplant patients.